Acorai Machine Learning Generalization (MLG) Study

NCT ID: NCT05835024

Last Updated: 2024-12-03

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

1602 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-08-15

Study Completion Date

2024-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Acorai is developing a non-invasive monitoring system for the estimation of intracardiac hemodynamic parameters in patients with suspected or confirmed heart failure, and/or pulmonary hypertension, who require hemodynamic assessment. The device will be intended as a companion test or clinical decision support tool to be used and interpreted by qualified healthcare professionals to aid standard-of-care clinical assessment in identifying hemodynamic congestion and supporting personalized treatment of heart failure and pulmonary congestion.

This study is part of the development of a non-invasive monitoring system for the estimation of intracardiac hemodynamic parameters. It will be conducted to collect the data needed to train the machine learning models retrospectively.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Heart Failure

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Participants phase 1

Phase 1: patients enrolled for a right heart catheterization procedure as part of their standard of care.

Acorai Sensor Data Collection (ASDC) system 1.0 - Phase 1

Intervention Type DEVICE

A supervised session that includes 10 minutes of patient information entry, 5 minutes of sensor recording time and 10 minutes of margin for setting up the system and patient, thus a total evaluation duration of approximately 25 minutes prior to the Right Heart Catheterization.

No follow-up period for the subjects will be required for this clinical investigation. Patients will be followed as per standard of care, at the hospital.

A single follow-up observational data collection will be conducted at 90 days, to collect the number of unplanned hospitalizations since the procedure visit. This does not involve active patient participation.

Participants phase 2

Phase 2: patients enrolled for a right heart catheterization procedure as part of their standard of care.

Acorai Sensor Data Collection (ASDC) system 1.0 - Phase 2

Intervention Type DEVICE

A supervised session that includes 10 minutes of patient information entry, 5 minutes of sensor recording time and 10 minutes of margin for setting up the system and patient, thus a total evaluation duration of approximately 25 minutes prior to the Right Heart Catheterization.

No follow-up period for the subjects will be required for this clinical investigation. Patients will be followed as per standard of care, at the hospital.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Acorai Sensor Data Collection (ASDC) system 1.0 - Phase 1

A supervised session that includes 10 minutes of patient information entry, 5 minutes of sensor recording time and 10 minutes of margin for setting up the system and patient, thus a total evaluation duration of approximately 25 minutes prior to the Right Heart Catheterization.

No follow-up period for the subjects will be required for this clinical investigation. Patients will be followed as per standard of care, at the hospital.

A single follow-up observational data collection will be conducted at 90 days, to collect the number of unplanned hospitalizations since the procedure visit. This does not involve active patient participation.

Intervention Type DEVICE

Acorai Sensor Data Collection (ASDC) system 1.0 - Phase 2

A supervised session that includes 10 minutes of patient information entry, 5 minutes of sensor recording time and 10 minutes of margin for setting up the system and patient, thus a total evaluation duration of approximately 25 minutes prior to the Right Heart Catheterization.

No follow-up period for the subjects will be required for this clinical investigation. Patients will be followed as per standard of care, at the hospital.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Subject is, at least, 18 years of age at the time of screening visit.
* Subject is willing and physically able to comply with the specified evaluations as per the clinical investigation plan, as assessed by the investigator.
* Subject is referred for invasive hemodynamic assessment with right heart cardiac catheterization.
* Patient has provided written informed consent using the Ethics Committee/ Institutional Review Board approved consent form.

Exclusion Criteria

* Discretionary exclusion when, in the opinion of the investigator, the inclusion of a potential subject is not in their best interest or not in the interest of compliant performance of the clinical investigation.
* Subjects who are pregnant are excluded in the US
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Acorai AB

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Conway Regional Cardiovascular Clinic

Conway, Arkansas, United States

Site Status

Baptist Health Medical Centre

Little Rock, Arkansas, United States

Site Status

Mayo Clinic

Jacksonville, Florida, United States

Site Status

Cleveland Clinic Martin Health

Stuart, Florida, United States

Site Status

Saint Luke's Hospital of Kansas City

Kansas City, Missouri, United States

Site Status

WakeMed

Raleigh, North Carolina, United States

Site Status

University of Pennsylvania

Philadelphia, Pennsylvania, United States

Site Status

Medical University of South Carolina (MUSC)

Charleston, South Carolina, United States

Site Status

Austin Heart Central and San Marcos

Austin, Texas, United States

Site Status

Austin Heart Round Rock

Austin, Texas, United States

Site Status

Onze-Lieve-Vrouwziekenhuis (OLV) Hospital Aalst

Aalst, , Belgium

Site Status

University of Ottawa Heart Institute

Ottawa, , Canada

Site Status

Mount Sinai Hospital Toronto

Toronto, , Canada

Site Status

Toronto General Hospital

Toronto, , Canada

Site Status

Rigshospitalet, University Hospital of Copenhagen

Copenhagen, , Denmark

Site Status

Sahlgrenska university hospital

Gothenburg, , Sweden

Site Status

Royal Brompton and Harefield Hospitals

London, , United Kingdom

Site Status

Southampton University Hospital

Southampton, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Belgium Canada Denmark Sweden United Kingdom

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

ASDC-1

Identifier Type: -

Identifier Source: org_study_id